Table 3.
Results of individual Bayesian dose adjustments of HDMTX from cycle one to cycle four (MTX dosing adaptations in cycles two to four), assuming conventional daily therapeutic drug monitoring of MTX plasma concentration
| Parameter | C1 | C2 | C3 | C4 |
|---|---|---|---|---|
| Simulated number of patients n | 10 000 | 10 000 | 10000 | 10 000 |
| Median AUCMTX (µmol l−1 h) | 876 | 1 008 | 1013 | 1 012 |
| 5% percentile (µmol l−1 h) | 559 | 877 | 873 | 861 |
| 95% percentile (µmol l−1 h) | 1 387 | 1 164 | 1164 | 1 170 |
| AUCMTX 1.000–1.100 µmol l−1 h (%) | 11 | 35 | 34 | 35 |
| AUCMTX <900 or >1.200 µmol l−1 h (%) | 67 | 11 | 11 | 10 |
C, cycle; AUC, area under the concentration–time curve; MTX, methotrexate.